Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune diseases

Netherlands Journal of Medicine

Volumn 61, Issue 9, 2003, Pages 273-277

  Bijl, M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTIMALARIAL AGENT; AUTOANTIBODY; DIPYRIDAMOLE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PHOSPHOLIPID ANTIBODY; PREDNISONE;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATORY DISEASE; ISCHEMIA; MORTALITY; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE; WEGENER GRANULOMATOSIS; ARTERIOSCLEROSIS; CHRONIC DISEASE; ENDOTHELIUM;

ARTERIOSCLEROSIS; AUTOIMMUNE DISEASES; CHRONIC DISEASE; ENDOTHELIUM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS;

EID: 1542469352     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Pearson JD. Normal endothelial cell function. Lupus 2000;9:183-8.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
3. Benzaquen LR, Yu H, Rifai N. High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment. Crit Rev Clin Lab Sci 2002;39:459-97.
4. Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 2001;104:63-7.
5. Ricker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-8.
6. Ricker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
7. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72.
8. Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990;344:254-7.
9. Hunt BJ. The endothelium in atherogenesis. Lupus 2000;9:189-93.
10. Byron MA, Allington MJ, Chapel HM, Mowat AG, Cederholm-Williams SA. Indications of vascular endothelial cell dysfunction in systemic lupus erythematosus. Ann Rheum Dis 1987;46:741-5.
11. Wellicome SM, Kapahi P, Mason JC, Lebranchu Y, Yarwood H, Haskard DO. Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1993;92:412-8.
12. Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CG. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long-term prospective study. Clin Exp Immunol 1994;97:439-44.
13. Stegeman CA, Tervaert JW, Huitema MG, Jong PE de, Kallenberg CG. Serum levels of soluble adhesion molecules intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin in patients with Wegener's granulomatosis. Relationship to disease activity and relevance during follow-up. Arthritis Rheum 1994;37:1228-35.
14. Dhillon R, Clarkson P, Donald AE, et al. Endothelial dysfunction late after Kawasaki disease. Circulation 1996;94:2103-6.
15. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol 1999;26:318-24.
16. Witte T, Hartung K, Sachse C, et al. Thrombomodulin in systemic lupus erythematosus: association with clinical and laboratory parameters. Rheumatol Int 1999;19:15-8.
17. Boehme MW, Raeth U, Galle PR, Stremmel W, Scherbaum WA. Serum thrombomodulin - a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity. Clin Exp Immunol 2000;119:189-95.
18. Boehme MW, Galle P, Stremmel W. Kinetics of thrombomodulin release and endothelial cell injury by neutrophil-derived proteases and oxygen radicals. Immunology 2002;107:340-9.
19. Belmont HM, Levartovsky D, Goel A, et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:1810-6.
20. Del Papa N, Sheng YH, Raschi E, et al. Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. J Immunol 1998;160:5572-8.
21. Carvalho D, Savage CO, Isenberg D, Pearson JD. IgG anti-endothelial cell autoantibodies from patients with systemic lupus erythematosus or systemic vasculitis stimulate the release of two endothelial cell-derived mediators, which enhance adhesion molecule expression and leucocyte adhesion in an autocrine manner. Arthritis Rheum 1999;42:631-40.
22. Papa ND, Raschi E, Moroni G, et al. Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro. Lupus 1999;8:423-9.
23. Yazici ZA, Raschi E, Patel A, et al. Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. Int Immune 2001;13:349-57.
24. Okawa-Takatsuji M, Aotsuka S, Uwatoko S, et al. Endothelial cell-binding activity of anti-U1-ribonucleoprotein antibodies in patients with connective tissue diseases. Clin Exp Immunol 2001;126:345-54.
25. Muller Kobold AC, Wijk RT van, Franssen CF, Molema G, Kallenberg CG, Tervaert JW. In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyangiitis. Clin Exp Rheumatol 1999;17:433-40.
26. Xu Q, Schett G, Perschinka H, et al. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation 2000;102:14-20.
27. Horkko S, Olee T, Mo L, et al. Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta (2)-glycoprotein 1 and oxidized low-density lipoprotein. Circulation 2001;103:941-6.
28. Swets BP, Brouwer DA, Tervaert JW. Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL. Clin Exp Immunol 2001;124:163-7.
29. Ettinger WH Jr, Hazzard WR. Elevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. J Clin Endocrinol Metab 1988;67:425-8.
30. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104:1887-93.
31. Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002;46:2957-63.
32. Cohn JN, Finkelstein S, McVeigh G, et al. Noninvasive pulse wave analysis for the early detection of vascular disease. Hypertension 1995;26:503-8.
33. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002;39:10-5
34. Doornum S van, McColl G, Jenkins A, Green DJ, Wicks IP. Screening for atherosclerosis in patients with rheumatoid arthritis: Comparison of two in vivo tests of vascular function. Arthritis Rheum 2003;48:72-80.
35. Wong M, Toh L, Wilson A, et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003;48:81-9.
36. Takase B, Uehata A, Akima T, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 1998;82:1535-8.
37. Neunteufl T, Katzenschlager R, Hassan A, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997;129:111-8.
38. Raza K, Thambyrajah J, Townend JN, et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation 2000;102:1470-2.
39. Lima DS, Sato EI, Lima VC, Miranda F Jr, Hatta FH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002;29:292-7.
40. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
41. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
42. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
43. Prior P, Symmons DP, Scott DL, Brown R, Hawkins CF. Cause of death in rheumatoid arthritis. Br J Rheumatol 1984;23:92-9.
44. Symmons DP, Jones MA, Scott DL, Prior P. Long-term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998;25:1072-7.
45. Park YB, Ahn CW, Choi HK, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002;46:1714-9.
46. Serrano CV Jr, Yoshida VM, Venturinelli ML, et al. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis 2001;157:505-12.
47. Teupser D, Bruegel M, Stein O, Stein Y, Thiery J. HMG-CoA Reductase Inhibitors Reduce Adhesion of Human Monocytes to Endothelial Cells. Biochem Biophys Res Commun 2001;289:838-44.
48. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-bet2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001;44:2870-8.
49. Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999;99:2871-5.
50. Muiesan ML, Salvetti M, Monteduro C, et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 1999;33:575-80.